Cosmo Pharmaceuticals NV

COPN

Company Profile

  • Business description

    Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology, and health tech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. The product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10, and CB-01-33.

  • Contact

    Sir John Rogerson’s Quay
    Riverside II
    Dublin2
    IRL

    T: +353 18170370

    E: [email protected]

    https://www.cosmopharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    332

Stocks News & Analysis

stocks

Eagers international foray

Our view on CanadaOne acquisition.
stocks

Tesla: Shares down despite record deliveries

We think the positive third-quarter numbers will be largely offset by a weak fourth quarter.
stocks

ASX listed share dominates their industry

Shares are currently fairly valued with a Wide Moat rating.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,288.1053.600.58%
CAC 408,081.5424.910.31%
DAX 4024,378.8043.76-0.18%
Dow JONES (US)46,758.28238.560.51%
FTSE 1009,491.2563.520.67%
HKSE27,140.92146.20-0.54%
NASDAQ22,780.5163.54-0.28%
Nikkei 22545,769.50832.771.85%
NZX 50 Index13,514.0962.330.46%
S&P 5006,715.790.440.01%
S&P/ASX 2008,987.4050.800.57%
SSE Composite Index3,882.7820.250.52%

Market Movers